VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2016

Dec 22, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2016-12-21

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-21	Common Stock	M	6500	$36.30	Acquired	274725	Direct
2016-12-21	Common Stock	S	4100	$73.65	Disposed	270625	Direct
2016-12-21	Common Stock	S	1300	$74.35	Disposed	269325	Direct
2016-12-21	Common Stock	S	800	$75.61	Disposed	268525	Direct
2016-12-21	Common Stock	S	300	$76.39	Disposed	268225	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-12-21	Stock Option (Right to Buy)	$36.30	M	6500	Disposed	2017-01-23	Common Stock (6500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	78200	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $73.65 (range $73.06 to $74.05).

F4: Open market sales reported on this line occurred at a weighted average price of $74.35 (range $74.07 to $75.00).

F5: Open market sales reported on this line occurred at a weighted average price of $75.61 (range $75.12 to $76.03).

F6: Open market sales reported on this line occurred at a weighted average price of $76.39 (range $76.13 to $76.52).

F7: Fully vested.